Israel defence minister claims breakthrough in developing Covid-19 antibody

To approach international firms to produce it on a commercial scale

testing, private laboratories, labs, vaccines, doctors, nurses, health, coronavirus
The statement said the antibody’s development had been completed and that the institute was in the process of patenting the find “and in the next stage, researchers will approach international companies to produce the antibody on a commercial scale”.
Agencies Jerusalem
2 min read Last Updated : May 06 2020 | 12:01 AM IST
Israeli Defence Minister Naftali Bennett has said that scientists at the country's main biological research institute have made a “significant breakthrough” in developing an antibody to the novel coronavirus, as the researchers wrapped up the development phase and moved to patent and mass produce the potential treatment.
 
Bennett visited the labs of the Israel’s Institute for Biological Research (IIBR), supervised by the Prime Minister’s Office and mandated to develop a vaccine for coronavirus, in Ness Ziona on Monday and was shown the “antibody that attacks the virus in a monoclonal way and can neutralise it within the bodies of those ill”, a statement from his office said.
 
The statement said the antibody’s development had been completed and that the institute was in the process of patenting the find “and in the next stage, researchers will approach international companies to produce the antibody on a commercial scale”.

“I am proud of the institute staff for this terrific breakthrough,” Bennett said, adding that “their creativity and the Jewish mind brought about this amazing achievement”.

In March, Israeli daily Ha'aretz, quoting medical sources, had reported that scientists at the institute had made a significant breakthrough in understanding the biological mechanism and qualities of the virus, including better diagnostic capability, production of antibodies for those who already have the virus and development of a vaccine.

It was not immediately clear if the breakthrough presented to Bennett was in addition to progress that was reported in late March, and no further details were provided.
 
The statement also did not specify whether human trials were conducted. Apparently, the IIBR conducted some clinical trials, PTI has learnt.
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirusisrael

Next Story